Try our Advanced Search for more refined results
Silverstrand Investments v. Amag Pharmaceuticals, Inc. et al
Case Number:
1:10-cv-10470
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
April 09, 2014
AMAG Pharma Fails To Shirk Drug-Risks Investor Suit
A Massachusetts federal court rejected a motion to dismiss a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks of iron deficiency treatment Feraheme, ruling Monday that the suit could continue in light of the First Circuit's reviving the case.
-
August 15, 2011
Judge Boots Investor Class Action Over Feraheme Risks
A Massachusetts federal judge on Thursday tossed a putative class action brought by AMAG Pharmaceuticals Inc. shareholders against the company and its underwriters for allegedly misleading investors about the risks associated with AMAG's injectable iron deficiency treatment Feraheme.